Kaempferide

Catalog No.S3879 Synonyms: 4'-Methylkaempferol, 4'-O-Methylkaempferol, Kaempferol 4'-methyl ether

For research use only.

Kaempferide (4'-Methylkaempferol, 4'-O-Methylkaempferol, Kaempferol 4'-methyl ether), a natural compound derived from the roots of kaempferia galanga, has a variety of effects including anti-carcinogenic, anti-inflammatory, anti-oxidant, anti-bacterial and anti-viral properties.

Kaempferide Chemical Structure

CAS No. 491-54-3

Purity & Quality Control

Related Other Products

Biological Activity

Description Kaempferide (4'-Methylkaempferol, 4'-O-Methylkaempferol, Kaempferol 4'-methyl ether), a natural compound derived from the roots of kaempferia galanga, has a variety of effects including anti-carcinogenic, anti-inflammatory, anti-oxidant, anti-bacterial and anti-viral properties.
In vitro

Kaempferide is able to induce apoptosis in the "side population" (SP, a subpopulation enriched with CSC in various cancers) cells in myeloma. It reverses the activity of drug efflux transporter[2]. Kaempferide is non-toxic to normal fibroblasts while inducing morphological changes, membrane flip-flop and nuclear membrane damage, characteristic of apoptosis in HeLa cells. It is highly cytotoxic to cervical cancer cells. Kaempferide-induced cytotoxicity is independent of cell cycle arrest[3].

In vivo Kaempferide (Kae) remarkably improves cardiac function, alleviates myocardial injury via a decrease in myocardial enzyme levels, and attenuates myocardial infarct size in a dose-dependent manner. It attenuates I/R-induced myocardial injury through inhibition of the Nrf2 and cleaved caspase-3 signaling pathways via a PI3K/Akt/GSK 3β-dependent mechanism. Preconditioning treatment with Kae significantly decreases serum TNF-α, IL-6, C-reactive protein (CRP), MDA, and ROS levels, while increases serum levels of SOD. Nuclear factor erythroid 2-related factor 2 (Nrf2) and cleaved caspase-3 expression levels are downregulated, while phospho-Akt (p-Akt) and phospho-glycogen synthase kinase-3β (p-GSK-3β) expression levels are upregulated[1]. Kaempferide is non-toxic as assessed by acute and chronic toxicity studies in Swiss albino mice in vivo[3].

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: KMS-11 cells
  • Concentrations: 4-64 μM
  • Incubation Time: 24 h
  • Method:

    Unfractionated cells are seeded at 20000 cells per well in a 96 well plate. After 24h of incubation with various concentration of KFD, PAR, and DMSO (vehicle control), MTS solution is added and absorbance at 490 nm is determined.

Animal Research:

[1]

  • Animal Models: Ischemia/Reperfusion (I/R) Rat Model (Adult Sprague Dawley (SD) rats)
  • Dosages: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 300.26
Formula

C16H12O6

CAS No. 491-54-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01199250 Not yet recruiting Other: Laboratory Biomarker Analysis Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation January 2100 --
NCT02861183 Not yet recruiting Device: OVT (Sodium Hyaluronate)|Device: Saline Epicondylitis|Tennis Elbow|Epicondylosis Anika Therapeutics Inc. September 2025 Not Applicable
NCT04542603 Not yet recruiting Drug: [11C]PiB and 18F-labeled DPA-714 PET scan Ovarian Cancer University of Alabama at Birmingham June 2025 Phase 1
NCT02442752 Withdrawn Drug: Dexlansoprazole Pediatric Gastroesophageal Reflux Disease Takeda June 15 2025 Phase 1
NCT03149211 Recruiting Drug: UB-421|Drug: current standard HAART treatment HIV-1 Infection United BioPharma April 1 2025 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Kaempferide | Kaempferide supplier | purchase Kaempferide | Kaempferide cost | Kaempferide manufacturer | order Kaempferide | Kaempferide distributor